Try our Advanced Search for more refined results
Life Sciences - February, 2015
289 articles
- Public Cos. Fill Week's IPO Void With Follow-On Offerings
- 8th Circ. Revives Fraud Claim In Blood Patent License Beef
- Fed. Circ. Won't Rehear Promega, Life Tech IP Dispute
- Texas Judge Dismisses Fen-Phen Conspiracy Suit As SLAPP
- Apple Still Top IP Target, But Pharma Takes More Fire
- February M&A Confirms Big Pharma Deals Still In Vogue
- Actavis Fights For Earlier 2nd Circ. Date In Antitrust Suit
- SEC Settles With Japanese Banker In $2B Olympus Scandal
- Taxation With Representation: Sullivan, Latham, Cravath
- Nikon Latest Japan Biz To Go Abroad With $400M Optos Buy
- Malin Biotech IPO To Raise Up To $365M For Acquisitions
- Dropped Herbalife Insider Case Leaves Questions Unanswered
- Minority Powerbrokers Q&A: Schiff Hardin's Sal Patel
- Target Hit With Class Action In Calif. Over Supplements
- Brain Tumor Drug Developer Celldex Prices $174M Offering
- PhRMA Seeks Quick Win In 340B Orphan Drug Suit
- Fed. Circ. Rejects Challenge To Patent Term Adjustments
- Deals Rumor Mill: Enel, Atkins, Terra Firma
- St. Jude Medical Puts Up $50M To Settle Investor Suit
- Shire Hits Par With Patent Suit Over Generic Adderall
- Dearth of Evidence Dooms False Ad Suits Against HGH Cos.
- J&J Units Look To Ditch Sunscreen SPF Labeling Claims
- Cold-EEZE Is 'Totally Ineffective,' False-Ad Suit Says
- $400M Pfizer Class Action Settlement On Track For Approval
- Market Rumors: Sixt, Sime Darby, Thyrocare
- Medtronic Ducks Liability Claims Over Brain Stimulators
- NY Federal Court Won't Rethink Cymbalta Labeling Suit
- Wal-Mart Faces Okla. Class Action Over Herbal Supplements
- Sullivan, Latham Steer Cyberonics-Sorin Med Tech Merger
- Olswang Snags 4 Ex-Winston IP Attys For London Office
- Bayer Unit Misled FDA On Birth Control, Law Firm Says
- Philly Risperdal Verdict Spells Trouble For J&J
- $327M Risperdal Fine Against J&J Unit Cut In Half
- Deals Rumor Mill: Pharmacyclics, Sycamore, HP
- High Court Won't Hear Anti-Vaxxer's Autism Arguments
- Cleary Gottlieb Leads Actavis In Another Historic Financing
- Supplier For MLB Doping Ring Sentenced To 18 Months
- LeClairRyan Snags Patent Pro From Shook Hardy
- 3 Biotechs Aim For Combined $300M In Follow-Ons
- Citizen Group Pushes For Full Ban Of Antifungal Med
- Sandoz Slams Amgen's Injunction Bid In Biosimilar Suit
- Teva May Have Little Impact On Claim Construction Appeals
- Mylan Says $107M Verdict Should Stand In Generic Paxil Fight
- 9th Circ. OKs Boiron's $5M Deal Ending False Ad Class Suit
- Schiff Says Glucosamine Class Can't Flake On $5M Deal
- Real Estate Rumor Mill: Cushman, BlackRock, Westport
- PTAB Nixes Genzyme Muscle Disease Treatment Patents
- Dutch Antitrust Watchdog Vows Scrutiny Of Pharma Sector
- Deals Rumor Mill: CSC, Lotte Group, Boston Scientific
- ClearCorrect Asks USPTO To Re-Examine Invisalign Patent
- When Customers And FCA Whistleblowers Collide
- Novartis Says Doc Deadline In FCA Suit Not Feasible
- Market Rumors: Wizz Air, Douglas, TravelCenters
- Human Egg Donors Seek To Intervene In Antitrust Pay Row
- J&J Hit With $2.5M Verdict In 1st Philly Risperdal Trial
- FDCA Preempts Maine Drug Importation Law, Court Says
- Shipman & Goodwin Nabs 3 IP Attys For DC Office
- Actavis Accuses NY AG Of Trying To 'Hijack' Antitrust Laws
- Lawmaker Calls For House Probe Of 'Superbug' Outbreak
- Accutane Ruling Shows Experts' Power To Shape Mass Torts
- Roche Thwarts Plaintiffs' Experts In NJ Accutane Litigation
- J&J Adds Up To $350M To $2.5B Hip Implant Settlement
- Epstein Becker Snags Cadre Of Health Pros From Sills Cummis
- FTC Targets App Makers For Cancer Detection Claims
- Insurers, AARP Back NY AG In Namenda Antitrust Suit
- Ex-Oriole Says Feds Hiding Evidence In Insider Trading Case
- High Court Won't Review Standing Rules For PTAB Appeals
- Deals Rumor Mill: 21st Century Fox, Arle, PTC Therapeutics
- Valeant's Return To Deal-Making Pays Off For This Firm
- FTC Approves Novartis' $16B GSK Oncology Buy With Fixes
- Actavis' Colitis Drug ANDA Triggers Patent Suit
- Bayer, Pharmacia Blast Double Recovery Try For CERCLA Site
- High Court Won't Hear $72M Bayer MDL Fee Fight
- FDA Unveils Medical Device Surveillance Vision
- Justices Won't Hear Zoll's Attempt To Nix Philips Patents
- BMS To Pay Up To $1.25B For Cancer Drugmaker Flexus
- Class Decertified In Cobra Sex Energy False-Ad Suit
- Cancer Immunotherapy Developer Cellectis Eyes $115M IPO
- Japan's Sosei Keeps Pharma Deals Churning With $400M Buy
- Plaintiffs Look Beyond Labels And Toward Product Testing
- Allergan Fuels Tension Over Schedule 13D Disclosure
- Minority Powerbrokers Q&A: Epstein Becker's Clifford Barnes
- Valeant Acquires Fellow Pharma Co. Salix In $14.5B Deal
- This Week In Congress: Avoiding A DHS Funding Showdown
- Novartis Escapes Zometa Patient's Jaw Injury Suit
- 1st Circ. Cites Levine To Free Forest In Lexapro Label Suit
- FedEx Scores Partial Wins In DEA Subpoena Fight
- Hagens Berman Faces Call For Sanctions In Thalidomide Suit
- FDA Clears 1st At-Home DNA Test, Eases Future Hurdles
- Fen-Phen Claimants Properly Denied Claims, Third Circ. Says
- Impax To Settle Investors' Quality-Control Suit For $8M
- Aussies Greenlight $23B GSK-Novartis Deal With Divestments
- Deals Rumor Mill: Valeant, Sika AG, Berkshire Hathaway
- 3rd Circ. Says AWP Whistleblower Relied On Public Info
- First Philly Risperdal Mass Tort Case Heads To Jury
- Split 6th Circ. Revives Dow Corning Breast Implant Suit
- ITC Tells Google Invisalign Case Won't Cripple The Web
- Dendreon Gets OK For Sweetened $495M Sale To Valeant
- Ch. 15 Liquidator Renews Push For Paul Weiss Docs
- Bard To Settle Avaulta Mesh Suit Ahead Of Trial
- 7th Circ. Urged To Revive Suit Over Abbott Off-Label Scheme
- Knobbe Martens Boosts LA Office With Ex-St. Jude Counsel
- Blackstone-Backed Catalent Plans $629M Follow-On Offering
- In-House Counsel's Dirty 'Little' Secret: Data Leakage
- Ex-Va. First Lady Gets 1-Year Prison Term For Corruption
- Pa. High Court Won't Hear Fixodent Evidence Appeal
- Biotech CEO Admits Using Father-In-Law To Hide Sham Trades
- Calif. Court Urged To Fix 23andMe Arbitration Split
- Public Interest Groups Back NY AG In Namenda Appeal
- Zurich On Hook For IMS Health's Antitrust Defense
- SEC Wins Partial Judgment Against Atty In NFLer Stock Scam
- Former Merck Analyst Cops To Insider Trading
- FDA Sounds Alarm Amid 'Superbug' Outbreak
- Neurocrine Biosciences Seeks $250M In Public Offering
- FDA Delay Shows Generics Label Critics Gaining Ground
- Basic Research To Issue Refunds In Weight-Loss Pill Row
- Actavis To Offer $8.4B In Shares To Fund Allergan Takeover
- Four Ex-Lathrop IP Pros Join Fox Rothschild In NY, Denver
- Natrol Estate Floats Ch. 11 Plan Covering All Debts
- Steptoe Nabs 4 Attys Conflicted Out Of Locke Lord Edwards
- FTC Defends Disgorgement Bid In Cephalon Pay-For-Delay Suit
- Deals Rumor Mill: Snapchat, GE, Rodan & Fields
- Apotex Sends Latest Biosimilar Application To FDA
- Civil Rights Group Asks Ethics Board To Probe Top Ala. Judge
- Loestrin Buyers Teed Up For Appeal In Pay-For-Delay Suit
- Feds Drop Challenge To Subpoena In $10M Grant Fraud Case
- Nixon Peabody, Mintz Levin Seek Exit From Malpractice Row
- Masimo, Philips Spar Over Patent Counterclaim In $467M Row
- Pelvic Mesh Plaintiffs Say Cases Can Be Heard In Philly
- Novartis Improperly Withholding Docs, Whistleblower Says
- Venture-Backed Inotek Raises $40M In Downsized IPO
- Agriculture Biotech Co. Arcadia Biosciences Seeks $86.3M IPO
- Takeaways From NY's Dietary Supplement Investigation
- Boston Sci Pays J&J $600M To Settle Guidant Merger Suit
- J&J Drops Plaintiff Solicitation Discovery Bid In Mesh MDL
- Deals Rumor Mill: Japan Post Holdings, Lotte Group, Fosun
- Psychiatrist Agrees To Pay $3.8M In FCA Kickbacks Case
- Ala. AG Must Halt Same-Sex Marriage Suit, Couples Say
- AbbVie Says FTC Withholding Key Docs In Pay-For-Delay Suit
- Gilead Double-Patenting Ruling Is Routine, High Court Told
- Judge To Weigh Attempt To Revive Bayer FCA Claims
- RTI Fights For Interest On $340M Becton Antitrust Verdict
- FDA Eyes Alternatives To Generic-Drug Label Plan
- Ringleader In MLB Doping Scandal Gets 4 Years In Prison
- This Week In Congress: DHS Funding Looms In Recess
- Bayer Chided As Yaz Blood Clot MDL Case Gets Trial Date
- NY AG Says Actavis Trying To Shield Namenda Monopoly
- WL Gore Asks Full Fed. Circ. To Review $1B Patent Ruling
- Bard Expert To Partially Testify In Avaulta Trial In Mesh MDL
- FDA Unveils New Drug Compounding Policies
- Fixodent Injury MDL Members Urge High Court To Revive Suit
- 6 IPOs Draw $833M As Cos. See Mixed Reviews From Investors
- Illumina DNA Sequencing Patent Survives AIA Review
- AstraZeneca's Kid Asthma Drug Patent Deemed Obvious
- Walgreens Customer Wants Supplement Suits Consolidated
- Curbing Contingency Fee Arrangements With State AGs
- Takeda Hit With $1.3M In Punitive Damages In Pa. Actos Case
- Bellerophon Therapeutics Raises $60M In Market Debut
- Big Pharma At FCA Crossroads, Philly US Atty Says
- Insulin Device Company Valeritas Seeks $90M IPO
- Deal-Happy Actavis Unloads Pharma R&D Unit To TPG
- Teva May Impact Strategy For PTAB Trials And Appeals
- Roche Fights To Crush Thousands Of Accutane Suits In NJ
- Becton Wants Interest Axed On $340M Syringe Antitrust Loss
- Trustee Moves To Wipe Out Bankrupt Biotech Co.
- Deals Rumor Mill: Valeant, Centrica, Sumitomo Mitsui
- Medline Escapes Contract Suit Over ACA Tax
- Teva Pharmaceutical Kicks Off $1B Debt Offering
- Takeda Hit With $2.3M Verdict In Philly Actos Case
- Brazil Seeks Restrictions On Novartis-GSK Deal
- Sen. Floats Bill To Expand Injured Vets' Fertility Care
- Invitae Prices Upsized IPO As 2 Diagnostic Cos. Pull Back
- Ariz. Judge Docks U.S. $3,000 For Disclosing Taxpayer Info
- Jury Urged To Return Verdict Against Takeda In Actos Case
- Allergan Shareholder Withdraws Suit Over Spurned Valeant Bid
- Hedge Fund's Novel AIA Strategy Targets Acorda's MS Drug
- Teva Loses Bid For Sales Ban On Generic Copaxone
- GE's Imaging Drug Deal Is Antitrust Abuse, 9th Circ. Told
- Interpreting Stock Reactions To Reverse-Payment Settlements
- AstraZeneca Pays $7.9M To Settle Feds' Medco Kickback Suit
- Kaye Scholer Scores 3 Ex-Dickstein Shapiro IP Attys
- FTC OKs Merck Plan To Shed Heartworm Plant To Merial
- Teva Probe Reveals 'Likely' FCPA Transgressions
- DOL Pegs H-1B Prevailing Wage To Worker's Start Date
- Sidley Nabs M&A Veteran From Cooley For Silicon Valley Team
- Insurer Must Cover Meningitis Outbreak Suits, Liberty Says
- Calif. Cipro Case Puts Pay-For-Delay Deals Under Scrutiny
- 2 Health IT Initiatives To Know In 2015
- US Targets $1B Chinese Subsidies With Massive WTO Case
- How PTAB Is Addressing 'Inherent Anticipation'
- GCs Name Best Of The Best Attorneys
- Dendreon Takes $400M Valeant Bid, Nixes Ch. 11 Auction
- 5 Firms Boast The Most Client-Savvy Attorneys
- Weil Gotshal Atty Scolded Over Witness In Risperdal Trial
- GCs Give Top Marks To 7 Standout Associates
- GCs Name Cream Of The Crop Litigators
- GNC, Wal-Mart Hit With More Suits Over Herbal Supplements
- Fla. Law Claim Stands In $60M Eli Lilly Warehouse Heist Suit
- Zimmer Pitches Asset Sales Amid EU's Probe Of Biomet Buy
- FDA Rejects Auxilium Bid To Hamstring Rival Product
- Kilpatrick Snags 6-Atty IP, Life Sciences Team In DC
- Following The Factors That Have Impacted Biopharma Cos.
- Azur's Bid For Contract Clarity Tossed In $35M FazaClo Feud
- Icahn Hit With Insider Trading Suit Over Short-Swing Profits
- Boehringer Says Cephalon Ruling Can't Help Aggrenox Class
- NY AG Sparks Herbal Supplement Suits Against Retail Giants
- Wright Medical Plans $400M Convertible Notes Offering
- Jones Day Adds Ex-Squire Health Care Co-Chair In Boston
- NJ Plaintiff Drops Accutane Suit Ahead Of Expected Trial
- Deals Rumor Mill: Lanxess, IHH Healthcare, Tesco
- J&J Not Prejudiced By New Risperdal Expert, Pa. Judge Says
- Meningitis Outbreak Suits Centralized In Massachusetts
- Sanofi-Aventis Hit With Class Suit Over Drug Sales Practices
- Scientists Try to Subpoena Prosecutor In $10M Fraud Case
- Pa. Judge Won't Strike $2M Actos Verdict Against Takeda
- Ex-Merck Analyst To Plead Guilty To Stock-Tipping Scam
- There's A Lot To Like About Hamburg's Legacy At The FDA
- 1st Circ. Backs Dismissal Of Abiomed Heart Pump Fraud Suit
- Minority Powerbrokers Q&A: Paul Hastings' Preston Ratliff
- Myriad Settles With Quest In Cancer Gene Test Patent MDL
- CMS Finalizes Rule Changes For Medicare Advantage
- Bayer Lacks Standing To Dispute 'Flanax' Trademark
- Fat Loss Pill Buyers Fight For Class Cert. At 11th Circ.
- 4 IPOs Draw $1.33B As Strong 2015 Starts To Take Shape
- FDA Pulls Product At Device Co's NH Unit In $6M Deal
- FDA Wants Simpler Language On Drug Promos
- Mom Says She Only Learned Of Risperdal Risks Via Atty Ad
- MLB Doping Scandal Co-Conspirator Seeks Lighter Sentence
- GNC Latest Retailer Hit By Supplement Mislabeling Suit
- Deals Rumor Mill: Quinpario, Exponent PE, Fairfax Media
- Medtronic, DOJ Reach $3M FCA Deal Over Pain Treatment
- Calif. Research Co. Not Paying Study Participants, Suit Says
- Amgen Demands Injunction In Biosimilar Suit
- The State Of Play In 2015: Year Of The Regulator
- Taxation With Representation: Covington, Wilson Sonsini
- Olympus Enters Talks With DOJ To End Kickback, FCA Probe
- Locke Lord Adds IP Litigation Atty To San Francisco Office
- FDA Gets Supplement Co. Shut Down For Treatment Claims
- Ex-NFLer Can't Shake SEC Claims Over Pump-And-Dump
- Outgoing FDA Chief's Contentious Tenure Empowered Agency
- Life Sciences Public Offering Fervor Strengthens In 2015
- Bankrupt Dendreon Taps Valeant As $400M Stalking Horse
- Nexium Buyers Call Drug Cos. 'Serial' Antitrust Violators
- LifeCell Loses Laches Bid Over LifeNet's $35M Patent Award
- Medtronic Unit To Cough Up $1.25M To Settle FCA Suit
- Lerner David Snags Ex-McCarter & English IP Pro
- Wal-Mart, Target, Walgreen Sued Over Herbal Supplements
- Nexvet's $40M IPO Pricing Adds To Rough Day For Biotechs
- AstraZeneca Forks Over $600M For Actavis Respiratory Drugs
- Latham Lures 2 Finnegan Patent Pros To DC Office
- Amazon Skirts Class Suit Over Dangerous Diet Drug Sales
- FDA Chief Hamburg To Leave Agency
- Pfizer Inks $17B Deal For Biosimilars Giant Hospira
- Former Patton Boggs Bigwig Takes FDA Chops To Polsinelli
- FDA Mulls Clearing Abilify Rival Based On Single Trial
- $1.25M Accentia Shareholder Settlement Wins Green Light
- Deals Rumor Mill: BT PLC, Total SA, Cinven
- Alabama Petitions High Court To Stay Gay Marriage Ruling
- Market Rumors: Total, Jasmine, GlaxoSmithKline
- Mintz Levin Adds IP Attys From Kilpatrick, Womble Carlyle
- Zoetis Hands Ackman 2 Board Seats To Head Off Proxy Fight
- FDA To Ease Access To Experimental Drugs
- Can Congress Coalesce Around The 21st Century Cures Bill?
- Avoid Spoliation Anxiety With Litigation Readiness Plans
- Human Egg Donors Win Partial Cert. In Antitrust Pay Row
- FTC To Get 1st Solo Crack At Cephalon Pay-For-Delay Claims
- Pfizer Can't Duck 10 Lipitor Diabetes Claims
- Endo, Others Look To Pare State Claims In Lidoderm MDL
- NJ Court Backs Strict Enforcement Of Generic Drug Settlement
- J&J Can't Get Mistrial Over Risperdal Expert, Pa. Judge Says
- FDA Rips Apotex's 'Utterly Misguided' Inspection Response
- Cubicin Correction Certificate Dooms Patent, Fed. Circ. Told
- Schiff Nutrition Foes Can't Halt $5M Pact's Approval Process
- FDA's Lab Test Oversight Draws Heavy Fire, Support
- Hahn Loeser Opens Calif. IP Practice With Davis Wright Team
- 2015 Will Be A Watershed Moment For Biosimilars
- Wal-Mart, Target, Others Must Pull Herbs From Shelf: NY AG
- Cravath Guides Mylan's $800M Female Health Care Assets Buy
- Myriad Settles 2 More Suits Over Cancer Test Patent
- Teva Asks Judge To Bar Generic Copaxone During Remand
- Genetic Testing Co. Invitae Eyes $80M IPO
- HHS Eyes $400B Savings In 2016 Budget Blueprint
- Judge Slams Drinker Biddle, Weil's Bid To Bar Risperdal Expert
- Obama Drug Plan To Rein In Patents, Increase HHS Scrutiny
- Takeda Expert Says Actos Didn't Cause Man's Bladder Cancer
- Merck Says Investor Suits Over Vytorin Study Filed Too Late
- AstraZeneca, Ranbaxy Scoff At Request For New Nexium Trial
- Robotic Surgery Co. Unveils $1B Buyback Program
- Pa. Court Clarifies Actavis Rule-Of-Reason Analysis